Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
1257 | 2758 | 48.1 | 88% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
419 | 3 | ADENOVIRUS//MERKEL CELL CARCINOMA//GENE THERAPY | 28518 |
564 | 2 | GENE THERAPY//ADENOVIRUS//HUMAN GENE THERAPY | 14456 |
1257 | 1 | ADENO ASSOCIATED VIRUS//AAV//POWELL GENE THER Y | 2758 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | ADENO ASSOCIATED VIRUS | authKW | 1614193 | 15% | 35% | 414 |
2 | AAV | authKW | 927837 | 8% | 40% | 210 |
3 | POWELL GENE THER Y | address | 485170 | 4% | 37% | 119 |
4 | GENE THER Y | address | 419605 | 12% | 12% | 319 |
5 | CELLULAR MOL THER Y | address | 311983 | 2% | 46% | 61 |
6 | AAV VECTORS | authKW | 264096 | 2% | 47% | 51 |
7 | MOLECULAR THERAPY | journal | 232815 | 10% | 8% | 273 |
8 | GENE THER Y PROGRAM | address | 223210 | 4% | 19% | 104 |
9 | HUMAN GENE THERAPY | journal | 204180 | 9% | 7% | 248 |
10 | HUMAN GENE THERAPY METHODS | journal | 173377 | 2% | 31% | 51 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Virology | 36656 | 28% | 0% | 768 |
2 | Medicine, Research & Experimental | 32486 | 41% | 0% | 1117 |
3 | Biotechnology & Applied Microbiology | 24077 | 40% | 0% | 1095 |
4 | Genetics & Heredity | 21914 | 37% | 0% | 1028 |
5 | Biochemistry & Molecular Biology | 842 | 18% | 0% | 510 |
6 | Hematology | 429 | 5% | 0% | 127 |
7 | Biochemical Research Methods | 150 | 3% | 0% | 95 |
8 | Cell Biology | 76 | 5% | 0% | 135 |
9 | Cell & Tissue Engineering | 25 | 0% | 0% | 10 |
10 | Neurosciences | 12 | 4% | 0% | 114 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | POWELL GENE THER Y | 485170 | 4% | 37% | 119 |
2 | GENE THER Y | 419605 | 12% | 12% | 319 |
3 | CELLULAR MOL THER Y | 311983 | 2% | 46% | 61 |
4 | GENE THER Y PROGRAM | 223210 | 4% | 19% | 104 |
5 | CELLULAR MOL THER EUT | 111227 | 1% | 30% | 34 |
6 | UNC GENE THER Y | 98611 | 1% | 64% | 14 |
7 | GENET THER EUT | 92450 | 1% | 21% | 39 |
8 | EXCELLENCE REGENERAT HLTH BIOTECHNOL | 85147 | 0% | 77% | 10 |
9 | U649 | 72445 | 0% | 55% | 12 |
10 | ABRAMSON 310A | 55349 | 0% | 100% | 5 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | MOLECULAR THERAPY | 232815 | 10% | 8% | 273 |
2 | HUMAN GENE THERAPY | 204180 | 9% | 7% | 248 |
3 | HUMAN GENE THERAPY METHODS | 173377 | 2% | 31% | 51 |
4 | GENE THERAPY | 125840 | 8% | 5% | 211 |
5 | MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT | 62230 | 1% | 18% | 32 |
6 | JOURNAL OF VIROLOGY | 53281 | 16% | 1% | 437 |
7 | JOURNAL OF GENE MEDICINE | 23745 | 2% | 4% | 55 |
8 | CURRENT GENE THERAPY | 23288 | 1% | 6% | 34 |
9 | HUMAN GENE THERAPY CLINICAL DEVELOPMENT | 8732 | 0% | 10% | 8 |
10 | VIROLOGY | 7460 | 4% | 1% | 113 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | ADENO ASSOCIATED VIRUS | 1614193 | 15% | 35% | 414 | Search ADENO+ASSOCIATED+VIRUS | Search ADENO+ASSOCIATED+VIRUS |
2 | AAV | 927837 | 8% | 40% | 210 | Search AAV | Search AAV |
3 | AAV VECTORS | 264096 | 2% | 47% | 51 | Search AAV+VECTORS | Search AAV+VECTORS |
4 | REP78 | 155666 | 1% | 94% | 15 | Search REP78 | Search REP78 |
5 | ADENO ASSOCIATED VIRUS AAV | 139948 | 1% | 45% | 28 | Search ADENO+ASSOCIATED+VIRUS+AAV | Search ADENO+ASSOCIATED+VIRUS+AAV |
6 | ADENO ASSOCIATED VIRUS TYPE 2 | 133626 | 0% | 93% | 13 | Search ADENO+ASSOCIATED+VIRUS+TYPE+2 | Search ADENO+ASSOCIATED+VIRUS+TYPE+2 |
7 | ADENO ASSOCIATED VIRUS VECTOR | 117244 | 1% | 38% | 28 | Search ADENO+ASSOCIATED+VIRUS+VECTOR | Search ADENO+ASSOCIATED+VIRUS+VECTOR |
8 | GENE THERAPY | 115934 | 14% | 3% | 389 | Search GENE+THERAPY | Search GENE+THERAPY |
9 | RAAV | 111574 | 1% | 31% | 33 | Search RAAV | Search RAAV |
10 | AAV SEROTYPES | 78716 | 0% | 89% | 8 | Search AAV+SEROTYPES | Search AAV+SEROTYPES |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | SAMULSKI, RJ , MUZYCZKA, N , (2014) AAV-MEDIATED GENE THERAPY FOR RESEARCH AND THERAPEUTIC PURPOSES.ANNUAL REVIEW OF VIROLOGY, VOL 1. VOL. 1. ISSUE . P. 427 -451 | 156 | 78% | 27 |
2 | BUNING, H , PERABO, L , COUTELLE, O , QUADT-HUMME, S , HALLEK, M , (2008) RECENT DEVELOPMENTS IN ADENO-ASSOCIATED VIRUS VECTOR TECHNOLOGY.JOURNAL OF GENE MEDICINE. VOL. 10. ISSUE 7. P. 717-733 | 153 | 91% | 77 |
3 | BALAKRISHNAN, B , JAYANDHARAN, GR , (2014) BASIC BIOLOGY OF ADENO-ASSOCIATED VIRUS (AAV) VECTORS USED IN GENE THERAPY.CURRENT GENE THERAPY. VOL. 14. ISSUE 2. P. 86 -100 | 151 | 85% | 9 |
4 | MITCHELL, AM , NICOLSON, SC , WARISCHALK, JK , SAMULSKI, RJ , (2010) AAV'S ANATOMY: ROADMAP FOR OPTIMIZING VECTORS FOR TRANSLATIONAL SUCCESS.CURRENT GENE THERAPY. VOL. 10. ISSUE 5. P. 319 -340 | 188 | 71% | 38 |
5 | DISMUKE, DJ , TENENBAUM, L , SAMULSKI, RJ , (2013) BIOSAFETY OF RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS.CURRENT GENE THERAPY. VOL. 13. ISSUE 6. P. 434-452 | 170 | 68% | 20 |
6 | MINGOZZI, F , HIGH, KA , (2013) IMMUNE RESPONSES TO AAV VECTORS: OVERCOMING BARRIERS TO SUCCESSFUL GENE THERAPY.BLOOD. VOL. 122. ISSUE 1. P. 23-36 | 103 | 78% | 113 |
7 | SCHULTZ, BR , CHAMBERLAIN, JS , (2008) RECOMBINANT ADENO-ASSOCIATED VIRUS TRANSDUCTION AND INTEGRATION.MOLECULAR THERAPY. VOL. 16. ISSUE 7. P. 1189 -1199 | 133 | 92% | 64 |
8 | WU, ZJ , ASOKAN, A , SAMULSKI, RJ , (2006) ADENO-ASSOCIATED VIRUS SEROTYPES: VECTOR TOOLKIT FOR HUMAN GENE THERAPY.MOLECULAR THERAPY. VOL. 14. ISSUE 3. P. 316-327 | 105 | 91% | 333 |
9 | HENCKAERTS, E , LINDEN, RM , (2010) ADENO-ASSOCIATED VIRUS: A KEY TO THE HUMAN GENOME?.FUTURE VIROLOGY. VOL. 5. ISSUE 5. P. 555-574 | 142 | 79% | 23 |
10 | GRIEGER, JC , SAMULSKI, RJ , (2012) ADENO-ASSOCIATED VIRUS VECTOROLOGY, MANUFACTURING, AND CLINICAL APPLICATIONS.METHODS IN ENZYMOLOGY, VOL 507: GENE TRANSFER VECTORS FOR CLINICAL APPLICATION. VOL. 507. ISSUE . P. 229-254 | 105 | 85% | 61 |
Classes with closest relation at Level 1 |